{"id":32931,"date":"2025-04-23T14:59:06","date_gmt":"2025-04-23T12:59:06","guid":{"rendered":"https:\/\/ggba.swiss\/bern-based-ypsomed-pivots-with-chf-420-million-diabetes-unit-sale-to-tecmed\/"},"modified":"2025-04-23T15:02:13","modified_gmt":"2025-04-23T13:02:13","slug":"ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/","title":{"rendered":"Ypsomed se r\u00e9oriente avec la vente de son unit\u00e9 diab\u00e8te \u00e0 TecMed pour CHF 420 millions"},"content":{"rendered":"\n<p><a href=\"https:\/\/www.tecmed.com\/\">TecMed AG<\/a>, \u00e9galement bas\u00e9e \u00e0 Burgdorf et dirig\u00e9e par l&rsquo;ancien pr\u00e9sident d&rsquo;Ypsomed Willy Michel, va acqu\u00e9rir <a href=\"https:\/\/www.ypsomed.com\/en\/diabetes-care-mylife.html\">Ypsomed Diabetes Care AG<\/a> et ses activit\u00e9s de d\u00e9veloppement de pompes \u00e0 patch. La transaction devrait \u00eatre finalis\u00e9e au cours du second semestre 2025, sous r\u00e9serve de l&rsquo;obtention des autorisations r\u00e9glementaires.<\/p>\n\n\n\n<p>La d\u00e9cision d&rsquo;Ypsomed de se concentrer exclusivement sur les syst\u00e8mes d&rsquo;injection sous-cutan\u00e9e refl\u00e8te sa confiance dans le potentiel de croissance des solutions d&rsquo;autogestion de la sant\u00e9 et des th\u00e9rapies biologiques. Le produit de la vente servira \u00e0 financer l&rsquo;expansion de l&rsquo;activit\u00e9 de syst\u00e8mes d&rsquo;injection d&rsquo;Ypsomed, notamment deux nouveaux halls de production et un centre de conf\u00e9rence sur le site de Soleure. Cette cession lib\u00e8re \u00e9galement des capacit\u00e9s sur le site, qui seront d\u00e9sormais enti\u00e8rement consacr\u00e9es \u00e0 l&rsquo;activit\u00e9 principale d&rsquo;Ypsomed.<\/p>\n\n\n\n<p>L&rsquo;unit\u00e9 de soins du diab\u00e8te, mieux connue pour la solution mylife Loop et la pompe \u00e0 insuline YpsoPump, poursuivra ses activit\u00e9s sous le nom de TecMed AG. Elle sera fusionn\u00e9e avec les activit\u00e9s de d\u00e9veloppement de pompes patch de TecMed pour former un acteur sp\u00e9cialis\u00e9 dans les syst\u00e8mes de perfusion d&rsquo;insuline. La nouvelle soci\u00e9t\u00e9 sera bas\u00e9e \u00e0 Burgdorf et devrait employer environ 300 personnes, dont environ 200 employ\u00e9s actuellement bas\u00e9s \u00e0 Soleure qui seront transf\u00e9r\u00e9s dans le courant de l&rsquo;ann\u00e9e.<\/p>\n\n\n\n<p>Selon Ypsomed, la s\u00e9paration des deux activit\u00e9s permettra d&rsquo;am\u00e9liorer la concentration, la flexibilit\u00e9 et le succ\u00e8s \u00e0 long terme des deux soci\u00e9t\u00e9s. Pour TecMed, cette acquisition est l&rsquo;occasion de devenir un leader mondial dans le domaine de l&rsquo;innovation en mati\u00e8re de soins du diab\u00e8te, en mettant fortement l&rsquo;accent sur les technologies centr\u00e9es sur le patient.<\/p>\n\n\n\n<p>Cette transaction fait suite \u00e0 la revue strat\u00e9gique lanc\u00e9e par Ypsomed en novembre 2024, qui a suscit\u00e9 l&rsquo;int\u00e9r\u00eat de plus de 20 acheteurs potentiels. TecMed s&rsquo;est finalement impos\u00e9 comme le partenaire privil\u00e9gi\u00e9 \u00e0 l&rsquo;issue d&rsquo;un processus de due diligence approfondi.<\/p>\n\n\n\n<p>Ypsomed continue d&rsquo;explorer les opportunit\u00e9s de croissance internationale et \u00e9value actuellement plusieurs sites potentiels pour une nouvelle usine de fabrication aux \u00c9tats-Unis, dont la mise en service est pr\u00e9vue d&rsquo;ici 2027.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La soci\u00e9t\u00e9 medtech Ypsomed, bas\u00e9e \u00e0 Burgdorf, a annonc\u00e9 la vente de son activit\u00e9 de soins du diab\u00e8te \u00e0 TecMed AG pour un montant pouvant atteindre CHF 420 millions. Cette d\u00e9cision marque un tournant strat\u00e9gique important, qui positionne Ypsomed comme un \u00ab\u00a0pure player\u00a0\u00bb dans le domaine des syst\u00e8mes d&rsquo;auto-injection pour ses partenaires pharmaceutiques et biotechnologiques du monde entier.<\/p>\n","protected":false},"author":6,"featured_media":32928,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1188,1154,1181,1163],"class_list":["post-32931","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-healthcare-fr-2","tag-investment-fr-2","tag-medical-devices-fr","tag-medtech-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ypsomed vend son unit\u00e9 diab\u00e8te \u00e0 TecMed pour CHF 420 millions<\/title>\n<meta name=\"description\" content=\"Ypsomed a annonc\u00e9 la vente de son activit\u00e9 de soins du diab\u00e8te \u00e0 TecMed AG pour un montant pouvant atteindre CHF 420 millions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ypsomed vend son unit\u00e9 diab\u00e8te \u00e0 TecMed pour CHF 420 millions\" \/>\n<meta property=\"og:description\" content=\"Ypsomed a annonc\u00e9 la vente de son activit\u00e9 de soins du diab\u00e8te \u00e0 TecMed AG pour un montant pouvant atteindre CHF 420 millions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-23T12:59:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-23T13:02:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Ypsomed-Burgdorf-1180x811-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Ypsomed se r\u00e9oriente avec la vente de son unit\u00e9 diab\u00e8te \u00e0 TecMed pour CHF 420 millions\",\"datePublished\":\"2025-04-23T12:59:06+00:00\",\"dateModified\":\"2025-04-23T13:02:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/\"},\"wordCount\":408,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Ypsomed-Burgdorf-1180x811-1.jpg\",\"keywords\":[\"Healthcare\",\"Investment\",\"Medical Devices\",\"Medtech\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/\",\"name\":\"Ypsomed vend son unit\u00e9 diab\u00e8te \u00e0 TecMed pour CHF 420 millions\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Ypsomed-Burgdorf-1180x811-1.jpg\",\"datePublished\":\"2025-04-23T12:59:06+00:00\",\"dateModified\":\"2025-04-23T13:02:13+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Ypsomed a annonc\u00e9 la vente de son activit\u00e9 de soins du diab\u00e8te \u00e0 TecMed AG pour un montant pouvant atteindre CHF 420 millions.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Ypsomed-Burgdorf-1180x811-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Ypsomed-Burgdorf-1180x811-1.jpg\",\"width\":1180,\"height\":811,\"caption\":\"Le si\u00e8ge social d'Ypsomed \u00e0 Burgdorf, dans le canton de Berne. La soci\u00e9t\u00e9 a vendu sa division diab\u00e8te \u00e0 TecMed AG, ce qui lui permettra de consacrer pleinement ses ressources au d\u00e9veloppement et \u00e0 l'expansion mondiale de syst\u00e8mes d'auto-injection sous-cutan\u00e9e pour ses partenaires pharmaceutiques et biotechnologiques. | \u00a9 Ypsomed\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ypsomed se r\u00e9oriente avec la vente de son unit\u00e9 diab\u00e8te \u00e0 TecMed pour CHF 420 millions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ypsomed vend son unit\u00e9 diab\u00e8te \u00e0 TecMed pour CHF 420 millions","description":"Ypsomed a annonc\u00e9 la vente de son activit\u00e9 de soins du diab\u00e8te \u00e0 TecMed AG pour un montant pouvant atteindre CHF 420 millions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/","og_locale":"fr_FR","og_type":"article","og_title":"Ypsomed vend son unit\u00e9 diab\u00e8te \u00e0 TecMed pour CHF 420 millions","og_description":"Ypsomed a annonc\u00e9 la vente de son activit\u00e9 de soins du diab\u00e8te \u00e0 TecMed AG pour un montant pouvant atteindre CHF 420 millions.","og_url":"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-04-23T12:59:06+00:00","article_modified_time":"2025-04-23T13:02:13+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Ypsomed-Burgdorf-1180x811-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Ypsomed se r\u00e9oriente avec la vente de son unit\u00e9 diab\u00e8te \u00e0 TecMed pour CHF 420 millions","datePublished":"2025-04-23T12:59:06+00:00","dateModified":"2025-04-23T13:02:13+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/"},"wordCount":408,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Ypsomed-Burgdorf-1180x811-1.jpg","keywords":["Healthcare","Investment","Medical Devices","Medtech"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/","url":"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/","name":"Ypsomed vend son unit\u00e9 diab\u00e8te \u00e0 TecMed pour CHF 420 millions","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Ypsomed-Burgdorf-1180x811-1.jpg","datePublished":"2025-04-23T12:59:06+00:00","dateModified":"2025-04-23T13:02:13+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Ypsomed a annonc\u00e9 la vente de son activit\u00e9 de soins du diab\u00e8te \u00e0 TecMed AG pour un montant pouvant atteindre CHF 420 millions.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Ypsomed-Burgdorf-1180x811-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Ypsomed-Burgdorf-1180x811-1.jpg","width":1180,"height":811,"caption":"Le si\u00e8ge social d'Ypsomed \u00e0 Burgdorf, dans le canton de Berne. La soci\u00e9t\u00e9 a vendu sa division diab\u00e8te \u00e0 TecMed AG, ce qui lui permettra de consacrer pleinement ses ressources au d\u00e9veloppement et \u00e0 l'expansion mondiale de syst\u00e8mes d'auto-injection sous-cutan\u00e9e pour ses partenaires pharmaceutiques et biotechnologiques. | \u00a9 Ypsomed"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/ypsomed-se-reoriente-avec-la-vente-de-son-unite-diabete-a-tecmed-pour-chf-420-millions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Ypsomed se r\u00e9oriente avec la vente de son unit\u00e9 diab\u00e8te \u00e0 TecMed pour CHF 420 millions"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/32931","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=32931"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/32931\/revisions"}],"predecessor-version":[{"id":32933,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/32931\/revisions\/32933"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/32928"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=32931"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=32931"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=32931"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}